Drug development
Colin Kerr
Published: Monday, July 3, 2017
Novaliq GmbH has announced the successful application of a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid-based dry eye disease (DED) treatment approach, in collaboration with the University of Cologne, Germany.
“Based on solid results of our ongoing test series, we expect a significant impact of Novaliq’s first-in class Nov-07 programme, in comparison with existing DED drugs on an established DED mouse model,” said Philipp Steven MD, Principle Investigator, Ocular Surface Group at the Department of Ophthalmology, University of Cologne, Germany.
www.novaliq.com
Tags: industry
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.